Loading...
Response rates and remission durations have improved for patients with multiple myeloma since the advent of more effective induction regimens and autologous stem-cell transplant (ASCT) consolidation. Nonetheless, most patients experience disease progression within 3 to 4 years. To assess the role of maintenance lenalidomide after initial therapy to improve progression-free survival (PFS), investigators conducted three phase III, multicenter, randomized, double-blind, placebo-controlled trials involving previously untreated multiple myeloma patients.
In an industry-supported study by Palumbo and colleagues, 459 patients (aged ≥65) with newly diagnosed, symptomatic disease who were ineligible for ASCT were randomized to one of three regimens: …